MicroSectors FANG and Innovation 3X Leveraged ETN vs Humana Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 15.6× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Humana Inc pays a 0.91% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Humana Inc for 51 Days on average.
| FNGU | HUM | |
|---|---|---|
Market Cap | $2.98B | $46.49B |
Volume | 4,682,352 | 2,567,704 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $431.03 |
52-Week Low | $13.73 | $163.67 |
Typical Hold Time | 19 Days | 51 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $35.99, down 3.25% today. Technical indicators show a bullish trend with strong moving average support but neutral oscillators. The ETN faces significant volatility risks as highlighted by recent analysis showing it lost 87% during previous tech sector downturns. Support levels cluster around $33-35 with resistance at $37-39.
While leveraged exposure to AI leaders like Nvidia and Meta offers upside potential during tech rallies, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the potential for amplified returns against the documented vulnerability to sector corrections, requiring careful risk management in portfolio allocation.
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →